![](https://ml.globenewswire.com/media/0475d2c4-7600-4ac7-916e-3a5207fed122/small/uvaxbio-png.png)
Uvax Bio Appoints Kevin O’Neill as Interim Chief Executive Officer
NEWARK, Del., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Uvax Bio, LLC, (“Uvax” or “the Company”) a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP® protein-based vaccines, today …